NASDAQ:VICL - Vical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.31 +0.10 (+8.26 %)
(As of 07/20/2018 06:00 AM ET)
Previous Close$1.21
Today's Range$1.28 - $1.36
52-Week Range$1.02 - $3.70
Volume459,534 shs
Average Volume185,912 shs
Market Capitalization$26.61 million
P/E Ratio-1.30
Dividend YieldN/A
Beta1.22
Vical logoVical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the company's core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VICL
CUSIP92560210
Phone858-646-1100

Debt

Debt-to-Equity RatioN/A
Current Ratio18.27
Quick Ratio18.27

Price-To-Earnings

Trailing P/E Ratio-1.30
Forward P/E Ratio-1.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.82 million
Price / Sales2.07
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book0.38

Profitability

EPS (Most Recent Fiscal Year)($1.01)
Net Income$-12,960,000.00
Net Margins-144.80%
Return on Equity-32.93%
Return on Assets-27.09%

Miscellaneous

Employees74
Outstanding Shares21,820,000
Market Cap$26.61

Vical (NASDAQ:VICL) Frequently Asked Questions

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) issued its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.12. The biotechnology company earned $0.72 million during the quarter, compared to analysts' expectations of $2.10 million. Vical had a negative return on equity of 32.93% and a negative net margin of 144.80%. View Vical's Earnings History.

When is Vical's next earnings date?

Vical is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Vical.

What price target have analysts set for VICL?

2 analysts have issued twelve-month price targets for Vical's stock. Their predictions range from $3.50 to $3.50. On average, they expect Vical's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 167.2% from the stock's current price. View Analyst Ratings for Vical.

What is the consensus analysts' recommendation for Vical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Vical's key competitors?

Who are Vical's key executives?

Vical's management team includes the folowing people:
  • Mr. Vijay B. Samant, Chief Exec. Officer, Pres and Director (Age 65)
  • Mr. Anthony Alan Ramos, Chief Financial Officer & Principal Accounting Officer (Age 51)
  • Dr. Lawrence Russell Smith Ph.D., Sr. VP of Research (Age 57)
  • Mr. Keith D. Hall M.D., VP of Operations (Age 56)
  • Dr. Mammen P. Mammen Jr., M.D., Sr. VP of Clinical Devel. (Age 54)

Has Vical been receiving favorable news coverage?

News coverage about VICL stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vical earned a media sentiment score of 0.06 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Vical?

Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical's stock price today?

One share of VICL stock can currently be purchased for approximately $1.31.

How big of a company is Vical?

Vical has a market capitalization of $26.61 million and generates $13.82 million in revenue each year. The biotechnology company earns $-12,960,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Vical employs 74 workers across the globe.

How can I contact Vical?

Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected]


MarketBeat Community Rating for Vical (NASDAQ VICL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.